ArticleScientific reports2025
A pan-cancer analysis of the oncogenic and immunological roles of THOC3 in human cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic Profiling of Human Extracellular Vesicles Reveals Diagnostic Biomarkers for Colon Adenocarcinoma.Journal of extracellular vesicles · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a Limited number of studies on THO Complex Subunit 3 (THOC3) in tumors. The purpose of this study is to conduct a comprehensive analysis of various types of tumors to determine the role of THOC3 in tumor progression and to investigate its impact on immunity. Retrieved THOC3 expression data from various cancers in the TCGA database and analyzed it using R software (version 3.6.4) and its related packages; explored the differential expression of THOC3 in tumors, its correlation with prognosis, functional enrichment, and its relationship with tumor heterogeneity. The study also aimed to uncover the correlation between THOC3 and tumor immunity. THOC3 is differentially expressed in various tumors and normal samples, and is correlated with overall survival and progression-free time. The study found that THOC3 expression is strongly associated with tumor mutational burden, microsatellite deletion, and immune response. The expression of THOC3 is significantly correlated with immune cell infiltration, and THOC3 can regulate transcription output and mRNA splicing. Therefore, we speculate that THOC3 could serve as a therapeutic target for future anticancer therapies. THOC3 can serve as a novel specific biomarker for diagnosis and prognosis in pan cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.